Halozyme Therapeutics Stock Analysis (NASDAQ:HALO)

Add to My Stocks
$11.5 $0.42 (3.79%) HALO stock closing price Jan 20, 2017 (Closing)
Watch Robo Advisor Video of HALO Stock Analysis
Halozyme Therapeutics
Updated on : Jan 20, 2017
previous close
HALO 11.5 (0%)
S&P 500 2271.3 (0%)
Closing Price On: Jan 20, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Long Term Growth
5 Year CAGR:
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Cash Flow
Operating cash flow:
Net Income:
Recent Growth
Long Term Growth
Operating Margins
Net Margins
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Halozyme Therapeutics Analysis Video

87 5 2

View Halozyme Therapeutics stock analysis video. This is our HALO analyst opinion covering the buy and sell arguments for HALO stock.

Halozyme Therapeutics, Inc. Stock Rating (2.2/5)

Our Halozyme Therapeutics stock opinion is based on fundamentals of the company. This Halozyme Therapeutics stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy HALO stock?

  • Halozyme Therapeutics's revenue growth came in at 53.3% in 2016 Q3.
  • The company saw a significant growth in revenue with a 5 year CAGR of .

Should you sell HALO stock?

  • Halozyme Therapeutics registered a negative operating margin of -34.5% (average) over the Trailing Twelve Months (TTM).
  • Over the last 12 months, Halozyme Therapeutics had an average Net loss of -44.6%.
  • The lack of profits renders the PE ratio useless for HALO stock.
  • The company is trading at a price to sales multiple of 9.2, which is overvalued in comparison to the Medical-Biomed-Genetics industry average multiple of 4.4.
  • Halozyme Therapeutics has a negative FCF (Free Cash Flow) margin of -28.8%.

Comments on this video and Halozyme Therapeutics stock